Overall, since CtsS and CysC responded to AngII treatment ex vivo and in HTN, exploring opportunities to modulate AngII ligand dependent signaling and SGK-1 activity through pharmacologic targeting may represent a meaningful way to shift matrilysis. This evidence concerns the gene AGT and hypertensive disorder.